PerkinElmer, Inc., a global leader in Health Sciences and Photonics, today announced the acquisition of Avalon Instruments Limited, based in Belfast, Northern Ireland. The acquisition expands and complements PerkinElmer?s Molecular Spectroscopy product portfolio through adding a family of innovative bench-top dispersive Raman spectrometers.
PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced the acquisition of Avalon Instruments Limited, based in Belfast, Northern Ireland. The acquisition expands and complements PerkinElmer?s Molecular Spectroscopy product portfolio through adding a family of innovative bench-top dispersive Raman spectrometers. The Avalon Raman platforms support both bulk analysis and microscopic imaging, enabling scientists and technicians to gain more information about their samples with excellent reproducibility. Terms of the deal were not disclosed.
Raman spectroscopy identifies and characterizes the composition of both organic and inorganic materials in a wide range of applications. It is a complementary analysis technique to near infrared spectroscopy (NIR) and infrared spectroscopy (IR). Raman provides labs with the ability to analyze solids, liquids, powders, gels, slurries and aqueous solutions in bulk or to address variation in sample distribution with imaging. The technology is applicable to a diverse range of end markets, including pharmaceuticals, forensics and academia.
?Customers will now have a single dependable source for high-throughput IR, NIR and Raman, along with integrated software and accessories,? said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. ?The PerkinElmer Raman instrumentation is designed for intuitive use, minimal operator intervention, and highly reproducible results to help labs achieve a high level of throughput and productivity.?
?We are excited to join PerkinElmer and contribute to their innovative approach to product development and continuous improvement, along with becoming part of a global leader in customer service and support,? said Dr. Andrew Dennis, managing director, Avalon Instruments.
Coupled with ease-of-use, no special sample preparation or manual adjustments, semi-automated sample platforms and a significantly lower cost than other premium Raman products, Friel noted that labs can more easily incorporate Raman analysis into their routine testing programs to improve results and meet ever-increasing efficiency demands.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.